Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic peptide engineered to mimic the incretin hormone GLP-1, which the gut naturally releases after eating. Structurally modified with a fatty acid side chain to resist enzymatic degradation, semaglutide binds with high affinity to GLP-1 receptors throughout the body, including those in the hypothalamus, pancreas, and gastrointestinal tract.
Its mechanism of action is multi-targeted: semaglutide activates GLP-1 receptors in the brain's appetite centers to reduce hunger signaling, slows gastric emptying to prolong post-meal satiety, and enhances glucose-dependent insulin secretion from pancreatic beta cells. This coordinated effect across multiple organ systems results in reduced caloric intake, improved glycemic control, and sustained weight reduction when combined with lifestyle modifications.
Semaglutide was originally developed and FDA-approved for type 2 diabetes (Ozempic) and subsequently approved at higher doses for chronic weight management (Wegovy). The STEP clinical trial program, involving over 15,000 participants, demonstrated average weight reductions of 12-17% of body weight over 68 weeks, establishing semaglutide as one of the most effective pharmacological interventions for obesity.
This compounded formulation combines semaglutide at 2mg/mL with pyridoxine (vitamin B6) at 40mg/mL. The subcutaneous injectable route delivers near-complete bioavailability — significantly higher than oral alternatives, which face degradation in the GI tract. Vitamin B6 complements the metabolic effects of semaglutide by supporting over 100 enzyme reactions related to amino acid metabolism, neurotransmitter synthesis, and energy production during caloric restriction.
Clinician-supervised, delivered to your door.
